Hims & Hers Health (HIMS) reported Q3 earnings late Monday of $0.32 per diluted share, swinging from a loss of $0.04 a year earlier.
Analysts polled by Capital IQ expected EPS of $0.05.
Revenue in the quarter ended Sept. 30 was $401.6 million, up from $226.7 million a year earlier.
Analysts surveyed by Capital IQ expected $382.8 million.
The company expects Q4 revenue of between $465 million and $470 million. Analysts expect $421.1 million.
For full-year 2024, it now expects revenue between $1.46 billion and $1.47 billion. The company was previously looking at full-year revenue of $1.37 billion to $1.40 billion. Analysts expect $1.4 billion.
Price: 20.50, Change: +0.14, Percent Change: +0.69
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。